Macular Degeneration, Dry Clinical Trials
2 recruiting trials for Macular Degeneration, Dry. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Macular Degeneration, Dry clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Research is led by Medical University of Vienna (1), Ospedale San Raffaele (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is White light stimulation (other, 1 trial), followed by Pascal Synthesis 577 sub-threshold laser (Topcon Corporation, Tokyo, Japan), Pascal Synthesis 577 sham (Topcon Corporation, Tokyo, Japan).
Track Macular Degeneration, Dry trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Retinal Photoreceptor Outer Segment Length Before and After Light Stimulation - a Pilot Study
It has been shown that reactions of human retinal photoreceptors to a light stimulus can be measured with custom-made, research prototype optical coherence tomography (OCT)...
Subthreshold Laser Treatment for Reticular Pseudodrusen Secondary to Age-related Macular Degeneration
Prospective, randomized, controlled, longitudinal, interventional multicentric study involving patients with reticular pseudodrusen secondary to AMD. The objective of this study...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Macular Degeneration, Dry, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Macular Degeneration, Dry, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Macular Degeneration, Dry, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.